Long run, they're all dead

Zyprexa is not an exception. The organization of American corporations, as applied to pharmaceuticals, guarantees that executives and sales people will injure their customers to make a quick buck. These people have to be paid well to overcome any moral qualms they might have, but in any case, they will move on with their bonuses and stock grants long before any process to assign legal liability can retrieve them.

This is the reason we see so many bad drugs in the marketplace.

Long-term clawback provisions in statute, not left to mere case law, could help align incentives with a longer term set of interests and efficiencies that take into account something beyond the current quarter.